


Xia Wang, Jing-Jing Shi, Shu-Ling Zhang and Han-Bing Li*

Crystal structure of dibromido-bis[μ -1-[(2-methyl-1*H*-benzoimidazol-1-yl)methyl]-1*H*-benzotriazole- κ N]mercury(II), $C_{30}H_{26}Br_2HgN_{10}$



The crystal structure is shown in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.

Table 1: Data collection and handling.

Crystal:	Colourless prism
Wavelength:	Size $0.24 \times 0.20 \times 0.18$ mm
μ :	Mo $K\alpha$ radiation ($0.71073 \text{ \AA}$)
Diffractometer, scan mode:	77.6 cm^{-1}
$2\theta_{\max}$, completeness:	Xcalibur, ω
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$, R_{int} :	52.8° , $>99\%$
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	6535 , 3094 , 0.030
$N(\text{param})_{\text{refined}}$:	$I_{\text{obs}} > 2 \sigma(I_{\text{obs}})$, 2484
Programs:	196
	SHELX [7], CrysAlis ^{PRO} [8]

Source of material

The ligand 1-[(2-methyl-1*H*-benzoimidazol-1-yl)methyl]-1*H*-benzotriazole (0.04 mmol, 0.0105 g) in methanol (6 mL) was added dropwise to a methanol solution (6 mL) of $HgBr_2$ (0.04 mmol, 0.0144 g) in methanol. The resulting solution was allowed to stand at room temperature. After 2 weeks colourless crystals were obtained.

Experimental details

H atoms were generated geometrically and refined as riding atoms with $C-H = 0.93 \text{ \AA}$ and $U_{\text{iso}}(H) = 1.2$ times $U_{\text{eq}}(C)$ for aromatic H atoms, with $C-H = 0.97 \text{ \AA}$ and $U_{\text{iso}}(H) = 1.2$ times $U_{\text{eq}}(C)$ for methylene H atoms, and with $C-H = 0.96 \text{ \AA}$ and $U_{\text{iso}}(H) = 1.5$ times $U_{\text{eq}}(C)$ for methyl H atoms.

Discussion

Imidazole and benzotriazole derivatives have been widely used in the syntheses of complexes since they can act as polydentate ligands and function as bridging ligands [1, 2]. Many symmetric imidazole and benzotriazole ligands have been applied [3, 4]. However, studies involving asymmetric imidazole and benzotriazole ligands are rather rare [5, 6].

DOI 10.1515/ncrs-2016-0157

Received May 18, 2016; accepted September 5, 2016; available online September 27, 2016

Abstract

$C_{30}H_{26}Br_2HgN_{10}$, monoclinic, $C2/c$ (no. 15), $a = 15.5262(6) \text{ \AA}$, $b = 13.2099(7) \text{ \AA}$, $c = 14.8370(5) \text{ \AA}$, $\beta = 95.688(3)^\circ$, $V = 3028.1(2) \text{ \AA}^3$, $Z = 4$, $R_{\text{gt}}(F) = 0.0329$, $wR_{\text{ref}}(F^2) = 0.0561$, $T = 291(2) \text{ K}$.

CCDC no.: 1502533

*Corresponding author: Han-Bing Li, Pharmacy College, Henan University of Chinese Medicine, Zhengzhou, 450008, P. R. China, e-mail: wangxiawx83@126.com

Xia Wang and Shu-Ling Zhang: Pharmacy College, Henan University of Chinese Medicine, Zhengzhou, 450008, P. R. China

Jing-Jing Shi: Henan University of Chinese Medicine, Zhengzhou, 450008, P. R. China

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	x	y	z	U _{iso} [*] /U _{eq}
Hg1	0.5000	0.599472(19)	0.2500	0.04310(9)
Br1	0.36446(3)	0.70037(4)	0.19862(3)	0.05419(15)
N1	0.4768(2)	0.4742(2)	0.3552(2)	0.0370(8)
N2	0.4136(2)	0.3489(3)	0.4222(2)	0.0380(8)
N3	0.3603(2)	0.1793(3)	0.4198(2)	0.0432(9)
N4	0.3569(3)	0.1045(3)	0.4837(2)	0.0603(12)
N5	0.3669(3)	0.0177(3)	0.4452(3)	0.0709(13)
C1	0.6278(3)	0.4418(4)	0.4304(3)	0.0445(11)
H1	0.6548	0.4943	0.4025	0.053*
C2	0.6741(3)	0.3781(4)	0.4919(3)	0.0510(13)
H2	0.7334	0.3876	0.5051	0.061*
C3	0.6330(3)	0.3002(4)	0.5342(3)	0.0541(13)
H3	0.6658	0.2594	0.5757	0.065*
C4	0.5463(3)	0.2812(4)	0.5171(3)	0.0469(12)
H4	0.5194	0.2289	0.5455	0.056*
C5	0.5004(3)	0.3449(3)	0.4545(2)	0.0336(10)
C6	0.5397(3)	0.4242(3)	0.4121(2)	0.0344(10)
C7	0.4032(3)	0.4276(3)	0.3626(3)	0.0373(10)
C8	0.3178(3)	0.4549(4)	0.3160(3)	0.0588(13)
H8A	0.3209	0.5210	0.2896	0.088*
H8B	0.2754	0.4550	0.3589	0.088*
H8C	0.3017	0.4063	0.2692	0.088*
C9	0.3460(3)	0.2817(3)	0.4475(3)	0.0461(11)
H9A	0.3444	0.2838	0.5126	0.055*
H9B	0.2905	0.3049	0.4194	0.055*
C10	0.3718(3)	0.1377(4)	0.3378(3)	0.0426(11)
C11	0.3766(3)	0.0344(4)	0.3554(3)	0.0514(12)
C12	0.3886(3)	−0.0349(5)	0.2871(4)	0.0710(16)
H12	0.3915	−0.1041	0.2985	0.085*
C13	0.3960(3)	0.0027(6)	0.2030(4)	0.0768(18)
H13	0.4053	−0.0415	0.1561	0.092*
C14	0.3898(3)	0.1063(6)	0.1855(3)	0.0729(18)
H14	0.3940	0.1289	0.1267	0.088*
C15	0.3778(3)	0.1770(4)	0.2520(3)	0.0560(14)
H15	0.3740	0.2460	0.2400	0.067*

We are engaged in the synthesis of unsymmetrical *N*-heterocyclic ligands and synthesized compound 1-[(2-methyl-1*H*-benzoimidazol-1-yl)methyl]-1*H*-benzotriazole. As part of this study, we selected this compound as ligand and generate a new complex [Hg(C₁₅H₁₃N₅)₂Br₂], which is reported here.

The title compound is a mononuclear complex, located on a two-fold axis in the space group *C*2/*c*. As is shown in the figure, the Hg(II) atom is four-coordinated by two N atoms from two 1-[(2-methyl-1*H*-benzoimidazol-1-yl)methyl]-

1*H*-benzotriazole ligands and two Br atoms in a distorted tetrahedral coordination environment (with Hg–N bond length of 2.327(3) Å, with Hg–Br bond length of 2.5433(5) Å). The bond angles around Hg(II) ion range from 89.35 to 116.79°. In addition, the benzoimidazol rings in adjacent molecules are almost parallel. The average interplanar distance is 3.54 Å, which suggests π–π interactions.

Acknowledgements: This work was financially supported by the Science and Technology Department of Henan Province (No. 142102210458) and Foundation for University Key Teacher by the Henan Province (2013GGJS-090), and the Program for Innovative Research Team (in Science and Technology) in Henan College of Chinese Medicine (STITHCCM-2013XCXC02). The authors thank the Professor Hong-Wei Hou and Yu Zhu of Zhengzhou University for their help.

References

- Wang, L.; Wang, W.-Q.; Guo, D.: Design and syntheses of hybrid supramolecular architectures: based on [Fe(C₂O₄)₃]³⁻ metallocates and diverse organic cations. *CrystEngComm* **24** (2014) 5437–5449.
- Hu, M.-C.; Wang, Y.; Zhai, Q.-G.; Li, S.-N.; Jiang, Y.-C.; Zhang, Y.: Synthesis, crystal structures, and photoluminescent properties of the Cu(I)/X/α,ω-bis(benzotriazole)alkane hybrid family (X = Cl, Br, I, and CN). *Inorg. Chem.* **48** (2009) 1449–1468.
- Meng, X.-R.; Jin, S.-Z.; Hou, H.-W.; Du, C.-X.; Ng, S. W.: Self-assembly of four supramolecular architectures: From 0-D to 2-D frameworks based on an unsymmetrical *N*-heterocyclic ligand. *Inorg. Chem. Acta* **362** (2009) 1519–1527.
- Huang, M.-H.; Liu, P.; Wang, J.; Chen, Y.; Liu, Q.-Y.: Synthesis structure and luminescence of a double helical coordination polymer with a semirigid ligand: L = *N*-(4-pyridylmethyl)benzimidazole. *Inorg. Chem. Commun.* **9** (2006) 952–954.
- Wang, X.; Yang, H.-Y.; Zhang, C.; Yuan, J.; Yang, H.-X.: Crystal structure of bis[μ-1-[(2-ethyl-1*H*-imidazol-1-yl)methyl]-1*H*-benzotriazole-κ²*N*:*N'*]bis[dibromido]dimercury(II), C₂₄H₂₆Br₄Hg₂N₁₀. *Z. Kristallogr. NCS* **230** (2015) 361–362.
- Wang, X.; Niu, J.-L.: Bis[μ-1-[(2-ethyl-1*H*-imidazol-1-yl)methyl]-1*H*-benzotriazole]bis(iodidocadmium). *Acta Crystallogr.* **E67** (2011) m882.
- Sheldrick, G. M.: A short history of SHELX. *Acta Crystallogr.* **A64** (2008) 112–122.
- Agilent Technologies: CrysAlis^{PRO} Software system, version 1.171.36.21, Agilent Technologies UK Ltd, Oxford, UK, 2012.